Levofloxacin Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Levofloxacin Market is segmented by Application (Pneumonia, Skin Infection, Kidney Infection, Bladder Infection, and Other Applications) and Geography.

Market Snapshot

levofloxacin market overview
Study Period: 2018 - 2026
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 5.1 %
levofloxacin market key players

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The global levofloxacin market was anticipated to record a CAGR of nearly 5.1% during the forecast period. The rise in the cases of bacterial infectious diseases, along with the growing number of baby boomers, is the main factor driving the growth of this market. As per the World Health Organization, pneumonia accounts for 15% of all deaths of children under 5 years old, killing 8,08,694 children in 2017. High burden of antibiotic-resistant infections and emergence of multi-drug resistant pathogens have been augmenting the market.

Increasing efforts undertaken by major companies for the development of advanced products will also support market growth. Involvement of international organizations serves as a catalyst in the levofloxacin market. Funding bodies, such as BARDA, are supporting biotech companies with financial support to complete early stage development of their novel therapies for infectious diseases. Furthermore, supportive government legislation, such as the Generating Antibiotics Incentives Now (GAIN) Act, is anticipated to bolster the approval process. The legislation aims to promote the development of therapies for growing burden and severity of antibiotic-resistant infections. These factors are also supporting the development and uptake of levofloxacin antibiotics.

However, lack of awareness associated with infectious disease may hamper business growth in the future.

Scope of the Report

As per the scope of the report, Levofloxacin is an antibiotic that is sold under the trade name Levaquin and is used to treat many bacterial infections, such as pneumonia, acute bacterial sinusitis, and chronic prostatitis. This medication belongs to a class of drugs known as quinolone antibiotics. The levofloxacin market is segmented by application and geography.

By Application
Skin Infection
Kidney Infection
Bladder Infection
Other Applications
North America
United States
United Kingdom
Rest of Europe
South Korea
Rest of Asia-Pacific
Middle East & Africa
South Africa
Rest of Middle East & Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Pneumonia Segment Dominates the Market and is Expected to Continue the Same during the Forecast Period

  • Pneumonia, by application segment, is expected to dominate the global levofloxacin market through the forecast period. Increasing incidence of pneumococcal disease is a high impact rendering driver. Over the years, there has been a significant upsurge in the number of community-acquired and ventilator-associated bacterial pneumonia.
  • These infections pose treatment challenges for physicians due to high resistance to current treatment alternatives, thereby imposing a high-cost burden. According to the World Health Organization, The cost of antibiotic treatment for all children with pneumonia is estimated at around USD 109 million per year. The aforementioned factors are driving the demand for the product.
levofloxacin market trends

North America Dominates the Market and is Expected to Continue the Same during the Forecast Period

North America is leading, owing to the presence of major market players. Furthermore, factors such as the increasing prevalence of chronic diseases, treatment costs, technological advancements, and product launches are expected to drive regional growth. Also, various government initiatives aimed at the prevention and treatment of pneumonia are responsible for creating a positive impact across North America. For instance, the Integrated Global Action Plan for Pneumonia and Diarrhea by UNICEF and WHO is aimed at minimizing preventable child deaths due to diarrhea and pneumonia. This initiative is focused on interventions and services that raise awareness and increase access to treatment and preventive measures, flourishing the regional growth for the levofloxacin market.

Asia-Pacific is expected to show exponential growth throughout the forecast period. This growth can be attributed to the increased prevalence of pneumococcal disease, unmet patient needs, increased cases of antimicrobial resistance, and rise in disorders leading to weakened immune system, thereby, contributing to the growth of the region.

levofloxacin market analysis

Competitive Landscape

The market for levofloxacin is consolidated and consists of the global as well as local players. The consolidated environment is marked by key players extensively deploying sustainability strategies. Lupin Limited, Glenmark Pharmaceuticals, Dr. Reddy's Laboratories Ltd, and Zydus Cadila are some of the most notable companies. These companies are involved in new product development initiatives, mergers and acquisitions, and geographical expansion.

Table of Contents


    1. 1.1 Study Assumptions

    2. 1.2 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rising Number of Baby Boomers

      2. 4.2.2 Growing Incidence of Bacterial Infections

      3. 4.2.3 Supportive Government Legislation

    3. 4.3 Market Restraints

      1. 4.3.1 Lack of Awaeness Associated with Infectious Disease

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Application

      1. 5.1.1 Pneumonia

      2. 5.1.2 Skin Infection

      3. 5.1.3 Kidney Infection

      4. 5.1.4 Bladder Infection

      5. 5.1.5 Other Applications

    2. 5.2 Geography

      1. 5.2.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.2.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.2.3 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.2.4 Middle East & Africa

        1. GCC

        2. South Africa

        3. Rest of Middle East & Africa

      5. 5.2.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 Aden Healthcare

      2. 6.1.2 Allenge India Pharma

      3. 6.1.3 Alna Biotech Private Limited

      4. 6.1.4 Bestochem

      5. 6.1.5 DivineSavior.in

      6. 6.1.6 Dr. Reddy's Laboratories Ltd

      7. 6.1.7 Glenmark Pharmaceuticals

      8. 6.1.8 Lupin Limited

      9. 6.1.9 PAX HEALTHCARE

      10. 6.1.10 Zydus Cadila

    2. *List Not Exhaustive

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Levofloxacin Market market is studied from 2018 - 2026.

The Levofloxacin Market is growing at a CAGR of 5.1% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Zydus Cadila , Dr. Reddy's Laboratories Ltd. , LUPIN LIMITED , PAX HEALTHCARE , Allenge India Pharma are the major companies operating in Levofloxacin Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!